Ceapro Inc V.CZO

COVID AND THE HEART

[prophetoffactz]

During the presentation with the Angiogenesis Foundation Gilles said the focus for the avenanthramide pill clinical trial will be COVID, longCOVID, and the heart. Early in the pandemic Dr. William Li, with a former Commissioner of the US FDA, wrote a warning about the risk of a tsunami of heart issues due to COVID. It was written in the Washington Post. Perhaps once CZO's Phase I safety trial, which is scheduled to begin mid-November, is completed and it may be completed in the first half of 2024 if prior timelines hold, the Phase IIa portion will include actual COVID patients. Having a safety profile for a bioactive already believed safe and being able to generate efficacy data in actual COVID patients next year could be exciting. Recently the FDA approved its first anti-inflammation treatment for heart disease and one of the trial investigators is in charge of CZO's clinical trial. Given his stature in the field and the growing body of concern about COVID and the heart maybe CZO can generate some news coverage. The New York Times had an article today on COVID and the heart: 



Cardiologists’ leading theory for how Covid damages the heart and causes cardiovascular events is that it stimulates widespread inflammation.

The potential for cardiovascular complications doesn’t go away after someone has recovered from Covid. A large 2022 study tracking medical records of 691,455 patients in the United States found that people had a significantly higher risk of developing virtually all heart-related diseases in the year after a Covid infection. According to the research, people were 1.5 times more likely to have a stroke, nearly twice as likely to have a heart attack, and had between 1.6 and 2.4 times the risk of developing different types of arrhythmias.
Can Covid Damage Your Heart? A Look At Short- and Long-Term Health Risks - The New York Times (nytimes.com)

[prophetoffactz]

Gilles, "The Montreal Heart Institute program looking at avenanthramide as a potential anti-inflammatory product and mostly to look at longCOVID patients where they have shown a lot of inflammation symproms at the cardiovascular level." July 12, 2023 presentation  

[prophetoffactz]

Colchicine was the anti-inflammatory drug recently FDA approved for heart disease and inflammation. It set a new precedent for inflammation and heart disease. The trial investigator in charge of CZO's avenanthramide clinical trial worked on the FDA approved drug. He also worked on colchicine for COVID. Colchcine doesn't have an ideal safety profile and avenanthramide may be able to beat it

[prophetoffactz]

Gilles, "The Montreal Heart Institute program looking at avenanthramide as a potential anti-inflammatory product and mostly to look at longCOVID patients where they have shown a lot of inflammation symptoms at the cardiovascular level." July 12, 2023 presentation   Colchicine plus aspirin has been tested with positive results treating COVID inflammation. Dr. William Li also